Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women". [2] In India it is marketed under the brand name of Ibset.

Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
By mouth (ODT), IV
ATC code
  • None
Pharmacokinetic data
Elimination half-life5.8 hours
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass279.33 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the trade name Irribow.[3][4] and in India as Ibset . 'Elsewhere it is commonly sold under the trade name Nasea and in India as Nozia (150 μg/mL injection & 100 μg oral tablet).[5]


  1. Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342.
  2. "2008 News Releases - Astellas Pharma Inc". www.astellas.com.
  3. Summary in Japanese. Retrieved on September 4, 2012.
  4. "2013 News Releases | Astellas Pharma Inc". www.astellas.com. Retrieved 2018-04-06.
  5. Abridged prescribing information — Nasea (MIMS Philippines). Retrieved on June 13, 2008.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.